Reducing pneumococcal risk in people aged 65 years and over
Author(s)
Van Buynder, P
Griffith University Author(s)
Year published
2019
Metadata
Show full item recordAbstract
Disease due to pneumococcus (Streptococcus pneumoniae) remains a major source of illness in older people. Conjugated pneumococcal vaccines are used extensively in national paediatric programs, whereas a 23-valent polysaccharide vaccine is mainly used in older people and high-risk groups. Data from the Netherlands have led to licensing of a conjugated pneumococcal vaccine for older people in Australia. This review examines current recommendations on pneumococcal vaccines.Disease due to pneumococcus (Streptococcus pneumoniae) remains a major source of illness in older people. Conjugated pneumococcal vaccines are used extensively in national paediatric programs, whereas a 23-valent polysaccharide vaccine is mainly used in older people and high-risk groups. Data from the Netherlands have led to licensing of a conjugated pneumococcal vaccine for older people in Australia. This review examines current recommendations on pneumococcal vaccines.
View less >
View less >
Journal Title
Medicine Today
Volume
20
Issue
2 Suppl
Publisher URI
Copyright Statement
© 2019 Medicine Today Pty. Ltd.. Reproduced in accordance with the copyright policy of the publisher. Use hypertext link for access to the publisher's website.
Subject
Medical and Health Sciences